Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-046060
Filing Date
2024-11-14
Accepted
2024-11-14 17:18:51
Documents
77
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 2174409
2 ex10-14.htm EX-10.14 81675
3 ex10-15.htm EX-10.15 81016
4 ex31-1.htm EX-31.1 20523
5 ex31-2.htm EX-31.2 19844
6 ex32-1.htm EX-32.1 12035
  Complete submission text file 0001493152-24-046060.txt   10755294

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE evfm-20240930.xsd EX-101.SCH 64440
8 XBRL CALCULATION FILE evfm-20240930_cal.xml EX-101.CAL 71581
9 XBRL DEFINITION FILE evfm-20240930_def.xml EX-101.DEF 335611
10 XBRL LABEL FILE evfm-20240930_lab.xml EX-101.LAB 504190
11 XBRL PRESENTATION FILE evfm-20240930_pre.xml EX-101.PRE 422019
80 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 2009638
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36754 | Film No.: 241464357
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)